Literature DB >> 14528106

Favorable response to treatment of a child with T-cell-rich large B-cell lymphoma presenting with liver failure.

Rajeev K Sathiapalan1, Bo Hainau, Khalid Al-Mane, Asim F Belgaumi.   

Abstract

The authors describe the successful management of a child with T-cell-rich large B-cell lymphoma (TCRBCL) involving the lymph nodes and liver, causing severe hepatic dysfunction. After immunohistochemical confirmation of the diagnosis, the patient was treated initially with low-dose, non-hepatotoxic chemotherapy and irradiation to the porta hepatis. Chemotherapy was gradually escalated to intensified B cell-lymphoma treatment regimens (CHOP, CYVE, COPAdM) as liver function improved. Despite prompt and notable response in the lymph nodes, the intrahepatic nodular lesions persisted radiologically. Liver function tests normalized during the course of treatment. However, radiologic studies of the liver showed abnormal regeneration with a predominant left lobe overshadowing a tiny right lobe. The patient remains in remission more than a year after completion of treatment. Judicious use of chemotherapeutic agents with or without local radiotherapy may influence the outcome and survival in children with TCRBCL involving the liver and causing abnormal hepatic function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528106     DOI: 10.1097/00043426-200310000-00014

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

Review 1.  Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literature.

Authors:  Evan S Dellon; Shannon R Morris; Wozhan Tang; Cherie H Dunphy; Mark W Russo
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

2.  T-cell/histiocyte-rich large B-cell lymphoma in a child: A case report and review of literature.

Authors:  Chapman Wei; Chaplin Wei; Omar Alhalabi; Lei Chen
Journal:  World J Clin Cases       Date:  2018-06-16       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.